Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

NCT05902533 is registered in ClinicalTrials.gov with University of Cincinnati as lead sponsor.

NCT NCT05902533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05902533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
Lead sponsor
University of Cincinnati
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
August 14, 2023
Completion date
August 14, 2029
Enrollment
33 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer